tetano
Editor, Senior Moderator
Clin Infect Dis
. 2022 Aug 4;ciac637.
doi: 10.1093/cid/ciac637. Online ahead of print.
BNT162b2 mRNA Vaccination Against COVID-19 is Associated with Decreased Likelihood of Multisystem Inflammatory Syndrome in U.S. Children Ages 5-18 Years
Laura D Zambrano[SUP] 1 [/SUP], Margaret M Newhams[SUP] 2 [/SUP], Samantha M Olson[SUP] 1 [/SUP], Natasha B Halasa[SUP] 3 [/SUP], Ashley M Price[SUP] 1 [/SUP], Amber O Orzel[SUP] 2 [/SUP], Cameron C Young[SUP] 2 [/SUP], Julie A Boom[SUP] 4 [/SUP], Leila C Sahni[SUP] 4 [/SUP], Aline B Maddux[SUP] 5 [/SUP], Katherine E Bline[SUP] 6 [/SUP], Satoshi Kamidani[SUP] 7 [/SUP], Keiko M Tarquinio[SUP] 8 [/SUP], Kathleen Chiotos[SUP] 9 [/SUP], Jennifer E Schuster[SUP] 10 [/SUP], Melissa L Cullimore[SUP] 11 [/SUP], Sabrina M Heidemann[SUP] 12 [/SUP], Charlotte V Hobbs[SUP] 13 [/SUP], Ryan A Nofziger[SUP] 14 [/SUP], Pia S Pannaraj[SUP] 15 [/SUP], Melissa A Cameron[SUP] 16 [/SUP], Tracie C Walker[SUP] 17 [/SUP], Stephanie P Schwartz[SUP] 17 [/SUP], Kelly N Michelson[SUP] 18 [/SUP], Bria M Coates[SUP] 18 [/SUP], Heidi R Flori[SUP] 19 [/SUP], Elizabeth H Mack[SUP] 20 [/SUP], Laura Smallcomb[SUP] 21 [/SUP], Shira J Gertz[SUP] 22 [/SUP], Samina S Bhumbra[SUP] 23 [/SUP], Tamara T Bradford[SUP] 24 [/SUP], Emily R Levy[SUP] 25 [/SUP], Michele Kong[SUP] 26 [/SUP], Katherine Irby[SUP] 27 [/SUP], Natalie Z Cvijanovich[SUP] 28 [/SUP], Matt S Zinter[SUP] 29 [/SUP], Cindy Bowens[SUP] 30 [/SUP], Hillary Crandall[SUP] 31 [/SUP], Janet R Hume[SUP] 32 [/SUP], Manish M Patel[SUP] 1 [/SUP], Angela P Campbell[SUP] 1 [/SUP], Adrienne G Randolph[SUP] 2 33 [/SUP], Overcoming COVID-19 Investigators
Affiliations
Abstract
Background: Multisystem inflammatory syndrome in children (MIS-C), linked to antecedent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is associated with considerable morbidity. Prevention of SARS-CoV-2 infection or coronavirus disease 2019 (COVID-19) by vaccination might also decrease MIS-C likelihood.
Methods: In a multicenter case-control public health investigation of children ages 5-18 years hospitalized from July 1, 2021 to April 7, 2022, we compared the odds of being fully vaccinated (two doses of BNT162b2 vaccine ≥28 days before hospital admission) between MIS-C case-patients and hospital-based controls who tested negative for SARS-CoV-2. These associations were examined by age group, timing of vaccination, and periods of Delta and Omicron variant predominance using multivariable logistic regression.
Results: We compared 304 MIS-C case-patients (280 [92%] unvaccinated) with 502 controls (346 [69%] unvaccinated). MIS-C was associated with decreased likelihood of vaccination (aOR, 0.16 95% CI, 0.10-0.26), including among children ages 5-11 years (aOR, 0.22 95% CI, 0.10-0.52), ages 12-18 years (aOR, 0.10 95% CI, 0.05-0.19), and during the Delta (aOR, 0.06 95% CI, 0.02-0.15) and Omicron (aOR, 0.22 95% CI, 0.11-0.42) variant-predominant periods. This association persisted beyond 120 days after the second dose (aOR, 0.08, 95% CI, 0.03-0.22) in 12-18 year-olds. Among all MIS-C case-patients, 187 (62%) required intensive care unit admission and 280 (92%) vaccine-eligible patients were unvaccinated.
Conclusions: Vaccination with two doses of BNT162b2 is associated with reduced likelihood of MIS-C in children ages 5-18 years. Most vaccine eligible hospitalized patients with MIS-C were unvaccinated.
Keywords: COVID-19; MIS-C; Pfizer (BioNTech); children; vaccine effectiveness.
. 2022 Aug 4;ciac637.
doi: 10.1093/cid/ciac637. Online ahead of print.
BNT162b2 mRNA Vaccination Against COVID-19 is Associated with Decreased Likelihood of Multisystem Inflammatory Syndrome in U.S. Children Ages 5-18 Years
Laura D Zambrano[SUP] 1 [/SUP], Margaret M Newhams[SUP] 2 [/SUP], Samantha M Olson[SUP] 1 [/SUP], Natasha B Halasa[SUP] 3 [/SUP], Ashley M Price[SUP] 1 [/SUP], Amber O Orzel[SUP] 2 [/SUP], Cameron C Young[SUP] 2 [/SUP], Julie A Boom[SUP] 4 [/SUP], Leila C Sahni[SUP] 4 [/SUP], Aline B Maddux[SUP] 5 [/SUP], Katherine E Bline[SUP] 6 [/SUP], Satoshi Kamidani[SUP] 7 [/SUP], Keiko M Tarquinio[SUP] 8 [/SUP], Kathleen Chiotos[SUP] 9 [/SUP], Jennifer E Schuster[SUP] 10 [/SUP], Melissa L Cullimore[SUP] 11 [/SUP], Sabrina M Heidemann[SUP] 12 [/SUP], Charlotte V Hobbs[SUP] 13 [/SUP], Ryan A Nofziger[SUP] 14 [/SUP], Pia S Pannaraj[SUP] 15 [/SUP], Melissa A Cameron[SUP] 16 [/SUP], Tracie C Walker[SUP] 17 [/SUP], Stephanie P Schwartz[SUP] 17 [/SUP], Kelly N Michelson[SUP] 18 [/SUP], Bria M Coates[SUP] 18 [/SUP], Heidi R Flori[SUP] 19 [/SUP], Elizabeth H Mack[SUP] 20 [/SUP], Laura Smallcomb[SUP] 21 [/SUP], Shira J Gertz[SUP] 22 [/SUP], Samina S Bhumbra[SUP] 23 [/SUP], Tamara T Bradford[SUP] 24 [/SUP], Emily R Levy[SUP] 25 [/SUP], Michele Kong[SUP] 26 [/SUP], Katherine Irby[SUP] 27 [/SUP], Natalie Z Cvijanovich[SUP] 28 [/SUP], Matt S Zinter[SUP] 29 [/SUP], Cindy Bowens[SUP] 30 [/SUP], Hillary Crandall[SUP] 31 [/SUP], Janet R Hume[SUP] 32 [/SUP], Manish M Patel[SUP] 1 [/SUP], Angela P Campbell[SUP] 1 [/SUP], Adrienne G Randolph[SUP] 2 33 [/SUP], Overcoming COVID-19 Investigators
Affiliations
- PMID: 35924406
- DOI: 10.1093/cid/ciac637
Abstract
Background: Multisystem inflammatory syndrome in children (MIS-C), linked to antecedent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is associated with considerable morbidity. Prevention of SARS-CoV-2 infection or coronavirus disease 2019 (COVID-19) by vaccination might also decrease MIS-C likelihood.
Methods: In a multicenter case-control public health investigation of children ages 5-18 years hospitalized from July 1, 2021 to April 7, 2022, we compared the odds of being fully vaccinated (two doses of BNT162b2 vaccine ≥28 days before hospital admission) between MIS-C case-patients and hospital-based controls who tested negative for SARS-CoV-2. These associations were examined by age group, timing of vaccination, and periods of Delta and Omicron variant predominance using multivariable logistic regression.
Results: We compared 304 MIS-C case-patients (280 [92%] unvaccinated) with 502 controls (346 [69%] unvaccinated). MIS-C was associated with decreased likelihood of vaccination (aOR, 0.16 95% CI, 0.10-0.26), including among children ages 5-11 years (aOR, 0.22 95% CI, 0.10-0.52), ages 12-18 years (aOR, 0.10 95% CI, 0.05-0.19), and during the Delta (aOR, 0.06 95% CI, 0.02-0.15) and Omicron (aOR, 0.22 95% CI, 0.11-0.42) variant-predominant periods. This association persisted beyond 120 days after the second dose (aOR, 0.08, 95% CI, 0.03-0.22) in 12-18 year-olds. Among all MIS-C case-patients, 187 (62%) required intensive care unit admission and 280 (92%) vaccine-eligible patients were unvaccinated.
Conclusions: Vaccination with two doses of BNT162b2 is associated with reduced likelihood of MIS-C in children ages 5-18 years. Most vaccine eligible hospitalized patients with MIS-C were unvaccinated.
Keywords: COVID-19; MIS-C; Pfizer (BioNTech); children; vaccine effectiveness.